Kevin Do, MD
Neuromuscular Medicine · Tustin, CANPI 1104078880
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $18,309 of the $29,234 with a category attached, or 62.6%. Merz North America, Inc. accounts for 89.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $17,578 and has fallen 95.8% since, to $733 in 2025.
Across 185 payments — averaging $158.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$26K
- AbbVie$1K
- Solta Medical, A Division Of Bausch Health US, LLC$612
- Johnson & Johnson$362
- Revance Therapeutics, Inc.$232
- AVEO Pharmaceuticals, Inc.$173
- plus $722 from 18 others
Across 17 payments — averaging $6099.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galderma Laboratories, L.p.$98K
- Eli Lilly$6K
What the payments were for
- Consulting fees$2,0007%
- Travel & lodging$18,30963%
- Food & beverage$8,90830%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 69 | $26,070 |
| AbbVie(2 entities) | 46 | $1,063 |
| Solta Medical, A Division Of Bausch Health US, LLC | 7 | $612 |
| Johnson & Johnson(2 entities) | 17 | $362 |
| Revance Therapeutics, Inc. | 6 | $232 |
| AVEO Pharmaceuticals, Inc. | 7 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $94 |
| Amneal Pharmaceuticals LLC | 3 | $79 |
| Galderma Laboratories, L.p. | 5 | $78 |
| Octapharma USA, Inc. | 4 | $74 |
| Servier Pharmaceuticals LLC | 2 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $50 |
| Organon | 2 | $39 |
| Amgen | 1 | $35 |
| AstraZeneca | 1 | $35 |
| Bayer | 1 | $33 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Merck | 1 | $25 |
| Stimwave Technologies Incorporated | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$3,002
- BOTOX$128
- Clear & Brilliant$120
- DAXXIFY$107
How this compares
$29,234 in reported general payments places this provider in the 70th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $32,440 |
| EliquisApixaban | 23 | $15,817 |
| VascepaIcosapent Ethyl | 35 | $14,823 |
| JanuviaSitagliptin Phosphate | 19 | $10,737 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,308 |
| Paliperidone ErPaliperidone | 13 | $5,087 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $5,073 |
| Icosapent Ethyl | 17 | $4,697 |
| Atorvastatin Calcium | 215 | $1,857 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,358 |
| Metformin Hcl | 148 | $1,239 |
| Rivastigmine | 13 | $1,223 |
| Pantoprazole Sodium | 74 | $1,167 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 17 | $1,056 |
| Omeprazole | 73 | $951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $25 | $10,73719 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $79 | $56173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 neuromuscular medicine providers in California.
Other neuromuscular medicine in Tustin
- Samir MacwanRancho Mirage$983K
- Ali HabibOrange$445K
- Tahseen MozaffarOrange$428K
- Jeffrey RosenfeldFresno$361K
- John DayStanford$294K
- Marwa KaiseyWest Hollywood$264K
- Namita GoyalOrange$174K
- Ana Tesi RochaPalo Alto$154K
- Jay HanOrange$126K
- Steven CramerLos Angeles$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.